Carisma Therapeutics (CARM) Competitors $0.42 -0.02 (-5.35%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends CARM vs. GBIO, FBLG, PDSB, OVID, AVTE, HOWL, EPIX, RPTX, ANVS, and OPTNShould you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include Generation Bio (GBIO), FibroBiologics (FBLG), PDS Biotechnology (PDSB), Ovid Therapeutics (OVID), Aerovate Therapeutics (AVTE), Werewolf Therapeutics (HOWL), ESSA Pharma (EPIX), Repare Therapeutics (RPTX), Annovis Bio (ANVS), and OptiNose (OPTN). These companies are all part of the "pharmaceutical products" industry. Carisma Therapeutics vs. Generation Bio FibroBiologics PDS Biotechnology Ovid Therapeutics Aerovate Therapeutics Werewolf Therapeutics ESSA Pharma Repare Therapeutics Annovis Bio OptiNose Generation Bio (NASDAQ:GBIO) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, institutional ownership, earnings and analyst recommendations. Which has preferable valuation and earnings, GBIO or CARM? Carisma Therapeutics has higher revenue and earnings than Generation Bio. Generation Bio is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeneration Bio$18.58M4.28-$126.61M-$2.19-0.54Carisma Therapeutics$20.27M0.86-$86.88M-$1.56-0.27 Do institutionals & insiders believe in GBIO or CARM? 95.2% of Generation Bio shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 21.1% of Generation Bio shares are held by insiders. Comparatively, 12.6% of Carisma Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend GBIO or CARM? Generation Bio presently has a consensus target price of $7.50, indicating a potential upside of 530.25%. Carisma Therapeutics has a consensus target price of $4.94, indicating a potential upside of 1,082.10%. Given Carisma Therapeutics' higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than Generation Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Generation Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Carisma Therapeutics 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.43 Does the media refer more to GBIO or CARM? In the previous week, Carisma Therapeutics had 7 more articles in the media than Generation Bio. MarketBeat recorded 7 mentions for Carisma Therapeutics and 0 mentions for Generation Bio. Generation Bio's average media sentiment score of 0.00 beat Carisma Therapeutics' score of -0.10 indicating that Generation Bio is being referred to more favorably in the media. Company Overall Sentiment Generation Bio Neutral Carisma Therapeutics Neutral Is GBIO or CARM more profitable? Carisma Therapeutics has a net margin of -314.78% compared to Generation Bio's net margin of -782.86%. Generation Bio's return on equity of -104.85% beat Carisma Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Generation Bio-782.86% -104.85% -49.54% Carisma Therapeutics -314.78%-957.20%-96.39% Does the MarketBeat Community prefer GBIO or CARM? Generation Bio received 26 more outperform votes than Carisma Therapeutics when rated by MarketBeat users. However, 76.19% of users gave Carisma Therapeutics an outperform vote while only 70.00% of users gave Generation Bio an outperform vote. CompanyUnderperformOutperformGeneration BioOutperform Votes4270.00% Underperform Votes1830.00% Carisma TherapeuticsOutperform Votes1676.19% Underperform Votes523.81% Which has more volatility and risk, GBIO or CARM? Generation Bio has a beta of 2.66, indicating that its share price is 166% more volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. SummaryGeneration Bio beats Carisma Therapeutics on 10 of the 19 factors compared between the two stocks. Ad Crypto 101 MediaThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Carisma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CARM vs. The Competition Export to ExcelMetricCarisma TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.45M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.2710.5989.9717.18Price / Sales0.86195.801,116.21116.99Price / CashN/A57.1642.8937.86Price / Book0.635.094.784.78Net Income-$86.88M$151.83M$120.23M$225.60M7 Day Performance3.24%-2.13%-1.92%-1.23%1 Month Performance-50.71%-3.10%11.49%3.36%1 Year Performance-85.59%11.54%30.57%16.60% Carisma Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CARMCarisma Therapeutics3.6722 of 5 stars$0.42-5.3%$4.94+1,082.1%-85.4%$17.45M$20.27M-0.2720GBIOGeneration Bio2.7569 of 5 stars$1.15-0.9%$7.50+552.2%-30.0%$76.81M$18.58M-0.53150Positive NewsFBLGFibroBiologics1.8409 of 5 stars$2.16-2.7%$13.00+501.9%N/A$74.86MN/A0.0010Positive NewsPDSBPDS Biotechnology1.1426 of 5 stars$2.00+8.4%$11.67+484.8%-66.0%$74.63MN/A-1.5920Analyst ForecastNews CoverageOVIDOvid Therapeutics4.3822 of 5 stars$1.05+1.9%$4.04+284.8%-71.8%$74.56M$390,000.000.0060Positive NewsAVTEAerovate Therapeutics1.252 of 5 stars$2.57+1.6%$2.25-12.5%-86.4%$74.21MN/A-0.8551Short Interest ↓Positive NewsHOWLWerewolf Therapeutics3.7637 of 5 stars$1.67+0.9%$12.00+620.7%-44.8%$74.20M$3.39M-1.0840Positive NewsEPIXESSA Pharma3.3486 of 5 stars$1.67+1.5%$9.50+470.6%-73.8%$73.88MN/A-2.6550Earnings ReportPositive NewsGap UpRPTXRepare Therapeutics3.4043 of 5 stars$1.70-4.0%$7.00+311.8%-79.7%$72.27M$51.13M-0.89180High Trading VolumeANVSAnnovis Bio2.3136 of 5 stars$5.18-2.4%$32.17+521.0%-59.3%$71.47MN/A-1.193News CoverageOPTNOptiNose4.0257 of 5 stars$0.47+0.6%$3.00+533.2%-63.1%$71.46M$70.99M0.00190 Related Companies and Tools Related Companies Generation Bio Alternatives FibroBiologics Alternatives PDS Biotechnology Alternatives Ovid Therapeutics Alternatives Aerovate Therapeutics Alternatives Werewolf Therapeutics Alternatives ESSA Pharma Alternatives Repare Therapeutics Alternatives Annovis Bio Alternatives OptiNose Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CARM) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
